ejpmr, 2025, 12(10), 290-296

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

SJIF Impact Factor 7.065

Review Article

ISSN (O): 2394-3211

ISSN (P): 3051-2573

A COMPREHENSIVE COMPARATIVE ANALYSIS OF EMERGENCY USE AUTHORIZATION FRAMEWORKS: INDIA'S CDSCO AND THE U.S. USFDA

Dr. Ashok Kumar P.*, Sushmitha R., Abhishek G. R., Pavan B. Mylapur, Harshitha H. P., Emran Bhasha S.

Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 feet Road, Batwadi, Tumkur-572103. Karnataka, India.

***Corresponding Author: Dr. Ashok Kumar P.**
Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, 1st Left Cross, 3rd Block, Mahalakshmi Nagar, Near Railway Gate, 80 Feet Road, Batwadi, Tumkur-572103.Karnataka, India.
DOI: https://doi.org/10.5281/zenodo.17275461

Article Received on 20/08/2025 **Article Revised on 10/09/2025** **Article Accepted on 01/10/2025**

ABSTRACT

The global response to public health emergencies necessitates agile regulatory pathways for medical products. This article presents a comparative study of the Emergency Use Authorization (EUA) frameworks of India's Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (USFDA), two of the world's most influential regulatory bodies. The research dissects their legal frameworks, procedural flows, data requirements, and post-authorization surveillance, focusing on their application during the COVID-19 pandemic. The analysis reveals that while both agencies utilize a risk-benefit assessment, key differences emerge in their statutory origins, transparency, and data standards. The USFDA's pathway is rooted in a well-defined legal statute with a public, data-driven review, while the CDSCO's process is more adaptable and context-specific. The findings underscore that no single model is universally superior; each has strengths embedded in its legal and administrative landscape. This analysis serves as a foundation for a discussion on global best practices and concludes with a series of recommendations for strengthening these pathways and enhancing global preparedness for future health crises.

KEYWORDS: EUA, CDSCO, USFDA, COVID-19.

INTRODUCTION

The New Era of Global Health Crises

The 21st century has been marked by an increasing frequency of public health crises that demand a faster response than traditional regulatory processes can provide. While the COVID-19 pandemic is the most prominent example, threats from bioterrorism and outbreaks of novel diseases like Ebola and Zika have underscored the critical need for agile regulatory mechanisms. The core challenge lies in a fundamental regulatory dilemma: the tension between accelerating access to life-saving interventions and upholding the rigorous scientific standards necessary to ensure public safety. This dilemma places immense political, social, and economic pressure on regulatory agencies during a crisis.

This paper presents a comprehensive, comparative analysis of the Emergency Use Authorization (EUA) pathways of two major regulatory bodies: the **Central Drugs Standard Control Organization (CDSCO)** in India and the **U.S. Food and Drug Administration (USFDA)**. The research aims to answer several key questions: What are the legal and procedural differences between the CDSCO and USFDA EUA frameworks How do their data requirements and transparency levels compare and what lessons can be learned for future pandemic preparedness The analysis is based on a qualitative, comparative review of regulatory documents, policy statements, and scholarly literature, with a focus on pharmaceutical products and biologics. Its findings are significant for policymakers, industry professionals, and public health experts seeking to understand and improve emergency regulatory responses.

Theoretical and Ethical Foundations of Emergency Regulation

To understand EUA, one must first appreciate the traditional philosophy of drug regulation. The standard paradigm is built on a high standard of evidence to prove a product is definitively "safe and effective," a process that is meticulous but time-consuming. EUA represents a necessary departure from this standard, guided by a distinct set of ethical and legal principles.

The core ethical considerations that guide EUA decisions include **beneficence** (the duty to do good by providing access), **non-maleficence** (the duty to not harm by ensuring adequate safety review), and **justice** (ensuring equitable access to authorized products). A central challenge is achieving **informed consent** when a product's full safety and efficacy profile is not yet known. This places a heavy burden on regulators to ensure that healthcare providers and recipients are clearly

informed of the product's EUA status and its known risks and benefits.

Furthermore, national regulators do not operate in a vacuum. Global bodies like the **World Health Organization (WHO)**, with its Emergency Use Listing (EUL) procedure, and the **International Council for Harmonisation (ICH)**, which sets technical standards, play a crucial role in shaping and harmonizing national regulatory policies, fostering a more coordinated global response.



Figure 1: Flowchart of EUA Path.

In-Depth Overview of Regulatory Authorities:
India's Central Drugs Standard Control Organization (CDSCO)

Logo: CDSCO

The CDSCO is the national regulatory body for pharmaceuticals and medical devices in India, operating under the Ministry of Health & Family Welfare. As the regulatory arm for the "pharmacy of the world," its decisions have a profound global impact. It is headed by the Drugs Controller General of India (DCGI). Its primary functions include the approval of new drugs and clinical trials and the regulation of drug imports. A key challenge and feature of its operation is the coordination with State Drug Control Organizations in India's federal system. In the EUA process, the **Subject Expert Committee (SEC)**, a panel of independent experts, plays a crucial role by reviewing submitted data and providing pivotal recommendations to the DCGI.

The U.S. Food and Drug Administration (USFDA)

Logo: USFDA

The USFDA is a federal agency of the Department of Health and Human Services (HHS) and is widely regarded as a **"gold standard"** global regulator whose decisions often serve as a benchmark for other nations. Its key centres for drug and vaccine approvals are the Centre for Drug Evaluation and Research (CDER) and the Centre for Biologics Evaluation and Research (CBER). The FDA's modern regulatory power was largely established by the Food, Drug, and Cosmetic Act of 1938. Its rigorous, evidence-based approach is its hallmark and provides the backdrop for its EUA framework, which is a carefully carved-out exception to its standard procedures.

The Evolution of Emergency Use Authorization

The US Pathway: A Response to National Threats

The legal foundation for the modern U.S. EUA was born not from a natural pandemic but from the threat of bioterrorism, specifically the fear of CBRN (Chemical, Biological, Radiological, and Nuclear) agents like anthrax following the 2001 attacks. This led to the landmark. **Project BioShield Act of 2004**, which introduced Section 564 of the Federal Food, Drug, and Cosmetic (FD&C) Act. This is the legal basis for the USFDA's EUA authority. Subsequent legislation, like the **The Pandemic and All-Hazards Preparedness Act (PAHPA) of 2006** expanded the scope of EUA to include pandemics and other public health emergencies. The framework was tested during the H1N1 influenza pandemic in 2009 and the Ebola outbreak between 2014 and 2016, providing a critical blueprint for its unprecedented use during the COVID-19 pandemic.

The Indian Pathway: An Administrative Adaptation

In contrast, India's framework for emergency approvals was historically more fluid and based on administrative notifications rather than a specific, codified law. The primary legal instruments have always been the Drugs and Cosmetics Act of 1940 and its subsequent rules. A significant step toward modernization was the **New Drugs and Clinical Trials (NDCT) Rules, 2019**, which provided the legal and procedural foundation for the fast-track approval process that CDSCO would later rely on heavily. The COVID-19 pandemic acted as a catalyst, forcing CDSCO to formalize its expedited process for **"Restricted use in emergencies"** through a series of official notices and circulars. This evolution reflects a shift from a reactive approach to a more proactive, though still flexible, system.

Table 1: Overview of Regulatory Authorities and Legal Frameworks.

Parameter	CDSCO (India)	USFDA (USA)
Parent Ministry/Department	Ministry of Health and Family Welfare (MoHFW)	Department of Health and Human Services (HHS)
Key Leadership	Drugs Controller General of India (DCGI)	FDA Commissioner
Governing Legislation	Drugs & Cosmetics Act, 1940; NDCT Rules, 2019	Public Health Service (PHS) Act; Food, Drug & Cosmetic (FD&C) Act
Legal Basis for EUA	Not formally codified; based on executive flexibility under NDCT Rules	Legally codified under Section 564 of the FD&C Act
Key Advisory Body	Subject Expert Committee (SEC)	External Advisory Committees (e.g., VRBPAC)

The EUA Process, Conditions, and Data Requirements

Conditions for Authorisation

The criteria for granting an EUA differ in their codification. The USFDA operates under four clear statutory conditions: a declared emergency, evidence that the product **may be effective**, a favourable **benefit-risk balance**, and the **absence of adequate alternatives**. CDSCO's conditions are less formally codified but are practically similar, requiring a public health emergency, preliminary efficacy data, and a favourable risk-benefit balance as determined by the SEC.

Application and Data Requirements

Both agencies require comprehensive data, including preclinical animal studies, clinical trial data (Phases I, II, and III), and detailed information on Chemistry, Manufacturing, and Controls (CMC). To generate this data quickly, modern approaches like **adaptive clinical trials**—which allow for modifications to a trial based on interim results—became crucial during the pandemic. The USFDA's evaluation is guided by the **"totality of the evidence"** principle. In contrast, CDSCO has shown greater willingness to rely on clinical trial data from other "stringent regulatory authorities" (SRAs), allowing it to waive full-scale local trials in favour of a smaller.

"Bridging study" to confirm safety in the Indian population.

Review and Decision-Making

A defining feature of the USFDA is its transparency. For many significant EUAs, the FDA convenes a public meeting of an independent Advisory Committee (like the VRBPAC), where external experts publicly scrutinize the data. This public process is a powerful tool for building trust 10. CDSCO's process is less public-facing, with the SEC's deliberations being internal 11.



Figure 2: EUA Approval Process.

EUA in Action: Key Case Studies from the COVID-19 Pandemic

The application of these frameworks during the COVID-19 pandemic provides crucial insights.

The US Experience: Pfizer-BioNTech and Moderna

The USFDA's handling of the mRNA vaccines was a landmark of its transparent process. This was especially critical given the novelty of the mRNA technology itself. The public meetings of the **VRBPAC**, which debated Phase III data demonstrating over 95% efficacy, was vital in building public confidence and facilitating rapid uptake. These EUAs eventually transitioned to full FDA approval, further solidifying their safety profiles.

The Indian Experience: Covaxin and Covishield

CDSCO's approach was shaped by the need for a rapid response and a focus on bolstering domestic vaccine supply. For Covishield, it relied on foreign data, a decision whose global importance was magnified by the COVAX initiative's reliance on the Serum Institute of India's production. The approval of **Covaxin** was more controversial, as it was granted in "**clinical trial mode**" before its Phase III efficacy data were public. This high-risk decision was ultimately vindicated but highlighted the ethical challenges that arise when approvals precede peer-reviewed publications.

A Transnational Case: The Antiviral Remdesivir

The therapeutic drug Remdesivir offers a case of parallel regulatory action. The USFDA granted it an EUA in May 2020 based on trial data showing it reduced recovery time. Shortly after, **CDSCO** also granted an EUA for the drug to be produced by domestic manufacturers, based on similar criteria, demonstrating how global data can accelerate decisions across jurisdictions.

Figure 3: Comparative Case Study Of Key COVID-19 Vaccine EUAS.

Table 2: Comparative Case Studies of Key COVID-19 Vaccine EUAs.

Product	Developer/Manufacturer	Regulatory Body	EUA Date	Key Basis for Decision & Noteworthy Features
Pfizer-BioNTech Vaccine	Pfizer/BioNTech	USFDA	Dec 2020	Based on the Phase III trial showing 95% efficacy, Extensive public advisory committee review and briefings were held.
Moderna Vaccine	Moderna, Inc.	USFDA	Dec 2020	Similar to Pfizer, an mRNA-based vaccine with strong Phase III data was reviewed in a public forum.
Covaxin	Bharat Biotech	CDSCO	Jan 2021	Approved for "restricted use" based on interim Phase I/II data; lacked published Phase III efficacy data at the time, leading to controversy.
Covishield	Serum Institute of India / AstraZeneca	CDSCO	Jan 2021	Based on global trial data from AstraZeneca, bridging studies were conducted in India to confirm safety and immunogenicity.

Post-Authorization Surveillance and Public Trust

Post-authorization surveillance is essential for monitoring real-world safety. The USFDA employs a multifaceted system, including the publicly accessible **VAERS** and **FAERS** databases. It's important to note that these are passive surveillance systems, which are subject to biases and cannot prove causation on their own. To counteract this, the USFDA also uses active systems like the smartphone-based **V-safe**.

India's surveillance is managed through the **Pharmacovigilance Programme of India (PvPI)**, a national program that relies on a network of monitoring centres and mandates that manufacturers submit **PSURs**.

In recent years, there has been a global push to incorporate **Real-World Evidence (RWE)** from electronic health records, and to use **AI and machine learning** to analyse large datasets to detect safety signals faster, is an area of development for both agencies.

Table 3: Comparison of Post-Authorization Surveillance Systems.

Parameter	CDSCO (India)	USFDA (USA)
Primary System	Pharmacovigilance Programme of India (PvPI)	FDA Adverse Event Reporting System (FAERS), Vaccine Adverse Event Reporting System (VAERS)
Reporting Mechanism	Primarily passive, manual reporting from ADR Monitoring Centres (AMCs)	Mix of passive reporting (VAERS/FAERS) and active, tech-enabled reporting (V-safe)
Sponsor Reporting	Mandatory but loosely enforced submission of Periodic Safety Update Reports (PSURs)	Detailed and time-bound submission of safety data and progress reports
Public Access to Data	Low; internal reviews dominate, and public access to safety findings is limited	High; safety data from systems like VAERS is publicly accessible, with regular FDA updates.

Comprehensive Comparative Analysis and Recommendations

Strengths and Weaknesses USFDA's primary strengths are its legal clarity, scientific rigor, and public trust built through transparency. Its main weakness is that its multi-layered process can sometimes introduce bureaucratic delays. CDSCO's key strengths are its flexibility, adaptability, and speed of approval, particularly its focus on supporting domestic manufacturing. Its primary weakness is a lack of legal specificity and a transparency deficit, which can fuel misinformation and erode public trust.

Table 4: Overall Comparative Summary.

Regulatory Aspect	CDSCO (India)	USFDA (USA)
Governing Legislation	Drugs & Cosmetics Act, 1940; NDCT Rules, 2019	Public Health Service (PHS) Act; Food, Drug & Cosmetic (FD&C) Act
Legal Nature	Administrative interpretation of existing rules	Codified, statutory framework under Section 564 of the FD&C Act
Trigger for EUA	Ad hoc, based on MoHFW/SEC advisories	Formal declaration of a public health emergency by the HHS Secretary
Key Review Body	Subject Expert Committee (SEC)	Internal FDA teams & external Advisory Committees (e.g., VRBPAC)
Transparency Level	Limited; SEC deliberations are not public	High; mandatory public advisory meetings, publication of EUA letters
Risk Management Plan	Mandatory post-market surveillance under PvPI	Risk Evaluation & Mitigation Strategy (REMS) may be required
Fast-Track Pathways	Conditional approvals for national priorities	Formalized pathways: Fast Track, Breakthrough Therapy, etc.
Public Access to Info	Limited information on the CDSCO portal	High; public databases like Drugs@FDA and ClinicalTrials.gov

CONCLUSION: A VISION FOR A HYBRID FUTURE:

This comparative analysis concludes that both the CDSCO and the USFDA, in their own unique ways, have successfully adapted their regulatory processes to meet the unprecedented demands of a global pandemic. They have each demonstrated a commitment to the critical balancing act of weighing scientific rigor against urgent public health needs. The USFDA's pathway stands as a model of **statutory rigor and transparency**, rooted in a clear and well-defined legal framework. Its greatest strengths are its predictability and its commitment to public engagement, which are vital for building and maintaining public trust.

In contrast, the CDSCO's pathway is a model of **administrative flexibility and speed**. Its reliance on an evolving framework and its willingness to accept data from other international regulators enabled a swift response to a national crisis, highlighting its adaptability and focus on national self-reliance in a time of global supply chain challenges.

However, the study also identifies inherent weaknesses. The USFDA's process, while robust, can be perceived as slow and bureaucratic, a potential bottleneck in a fast-moving crisis. The CDSCO's process, while fast, has at times faced a deficit in transparency and public communication, which can lead to scepticism and erode public confidence.

The COVID-19 pandemic has redefined the regulatory landscape, proving that EUA is no longer a rare exception but a foundational tool in modern emergency preparedness. The broader implication is the need to couple this newfound regulatory agility with unwavering scientific integrity and ethical accountability to safeguard public trust. The ideal system of the future may be a hybrid, one that combines the **legal clarity and transparency of the USFDA** with the **administrative flexibility and speed of the CDSCO**. By learning from each other's experiences and embracing the work of international harmonization bodies like the **ICH** and **ICMRA**, both agencies can strengthen their preparedness for future public health emergencies, contributing to a more resilient and effective global response.



Figure 4: A Comprehensive Conclusion.

ACKNOWLEDGEMENT

The authors express their sincere gratitude to **Dr. Ashok Kumar P**, Department of Regulatory Affairs, Sree Siddaganga College of Pharmacy, for his valuable guidance, support, and encouragement throughout the course of this study. The authors also thank the institution for providing a conducive academic environment and access to relevant resources.

REFERENCES

1. Central Drugs Standard Control Organization (CDSCO). Available from: URL: https://cdsco.gov.in
2. U.S. Food and Drug Administration (USFDA). Emergency Use Authorization. Available from: URL:: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization
3. Ministry of Health and Family Welfare, Government of India. (2019). New Drugs and Clinical Trials Rules, 2019.
4. U.S. Congress. Federal Food, Drug, and Cosmetic Act (FD&C Act), Section 564.
5. World Health Organization (WHO). Emergency Use Listing (EUL) Procedure. Available from: URL :https://www.who.int/teams/regulation-prequalification/eul
6. Lurie N, Saville M. Emergency Use Authorization: A Pathway to COVID-19 Vaccines. New England Journal of Medicine, 2020; 383(24).
7. International Coalition of Medicines Regulatory Authorities (ICMRA). Available from: URL: http://www.icmra.info
8. U.S. Centres for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). Available from: URL: https://vaers.hhs.gov